Tal-Singer Ruth, Walsh Linda, Deuby Tim, Shaughnessy Angela, Hoth Karin F, Gascon Victor, Hintringer Susanne, Hass Nicole, Winders Tonya, Morgan Lucy, Thomashow Byron, Mannino David M
COPD Foundation, Miami, Florida, USA
Global Allergy and Airways Patient Platform (GAAPP), Vienna, Austria.
Thorax. 2022 Oct;77(10):1045-1047. doi: 10.1136/thorax-2022-219142. Epub 2022 Aug 15.
The 2021 purchase of the respiratory pharmaceutical company Vectura by Phillip Morris International has been criticised by the public health and medical community, as a conflict of interest, with little input to date, from the patient community or the public. To address this gap, the COPD Foundation, along with global partners, surveyed 1196 people with chronic respiratory disease. 70% were bothered by a tobacco company making an inhaler to treat lung conditions and 48% reported that they would want to switch inhalers if they knew that a tobacco company made or sold their inhaler devices. Patients care about who makes the therapies used to treat their diseases.
菲利普·莫里斯国际公司在2021年收购呼吸制药公司威克图拉的行为受到了公共卫生和医学界的批评，认为这存在利益冲突，而且迄今为止，患者群体和公众几乎没有参与意见。为了弥补这一差距，慢性阻塞性肺疾病基金会与全球合作伙伴一起，对1196名慢性呼吸道疾病患者进行了调查。70%的人对烟草公司生产治疗肺部疾病的吸入器感到困扰，48%的人表示，如果他们知道是烟草公司生产或销售他们的吸入器设备，他们会想要更换吸入器。患者关心治疗他们疾病的疗法是由谁生产的。
